Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence

THOMAS SJ CRABTREE, 1,2 RALPH A DEFRONZO, 3 ROBERT EJ RYDER, 2 CLIFFORD J BAILEY 4

Abstract
Imeglimin is a novel, first in-class, blood glucose-lowering agent which acts via a mitochondrial mechanism to enhance glucose-induced insulin secretion, decrease hepatic glucose output and increase glucose uptake by skeletal muscle. A systematic review and meta-analysis of randomised controlled clinical trials (RCTs) with imeglimin in adults with type 2 diabetes was undertaken. Of 45 articles identified, five were RCTs but, due to the format of the data, only three could be combined in a meta-analysis (total n=180 participants). A random-effects model found that imeglimin 1500 mg twice daily as monotherapy and add-on to metformin or sitagliptin was associated with reductions of HbA1c by −0.63% (95% CI −0.84 to −0.42) (−6.6 mmol/mol, 95% CI −8.8 to −4.4) and reductions of fasting plasma glucose by −0.52 mmol/L (95% CI −0.80 to −0.24) compared with placebo. Adverse events were minimal, mostly gastrointestinal, and without hypoglycaemia. It is concluded that imeglimin displays promising improvements in HbA1c and fasting plasma glucose and is generally well tolerated.

Br J Diabetes 2020;20:28-31

Key words: type 2 diabetes; mitochondria; imeglimin; glimins; tetrahydrotriazine, systematic review, meta-analysis

Introduction
Type 2 diabetes is the product of multiple pathogenic factors including insulin resistance, beta-cell dysfunction and many other disturbances that underlie the development of hyperglycaemia. 1 Current glucose-lowering medications taken as monotherapy or in combinations are often unable to reinstate normoglycaemia, indicating the need for new therapies with different modes of action. This paper focuses on imeglimin, a new type of glucose-lowering agent (a glimin) continuing after delays in phase 3 development for the treatment of type 2 diabetes.

Imeglimin is a tetrahydrotriazine that acts on mitochondria to increase flux through complex II of the respiratory chain, increasing ATP synthesis and reducing the production of reactive oxygen species. 2 Mitochondrial dysfunction has been shown to play an important pathogenic role in the development of type 2 diabetes, 3 and can be demonstrated in the normal, glucose-tolerant, insulin-resistant offspring of diabetic parents. 4 Studies in animal models have shown that imeglimin impacts the pathophysiology of type 2 diabetes mellitus by improving glucose-induced insulin secretion, increasing beta-cell mass, decreasing hepatic glucose output and increasing skeletal muscle glucose uptake. 2,5–8 Imeglimin may also protect endothelial cells from the effects of glucotoxicity with potential beneficial cardiovascular effects. 9–11

This systematic review and meta-analysis assesses the evidence from clinical trials of imeglimin compared with placebo or other established oral glucose-lowering drugs.

Methods
The word “imeglimin” was searched using the Ovid Medline and Embase databases and grey literature. Randomised controlled trials or cluster randomised controlled trials conducted with imeglimin against placebo and/or other oral glucose-lowering agents in human subjects were considered for inclusion. There were no restrictions of language or timeframe. Primary outcomes of interest for meta-analysis (where quantity and quality of data allowed) were HbA1c and fasting plasma glucose (FPG) following treatment with imeglimin. Secondary outcomes included adverse events and hypoglycaemia. Identified publications were assessed independently by two reviewers. A third reviewer was available but not required to adjudicate any disagreement over inclusions/exclusions. References listed in identified publications were cross-checked for any publications missed by the initial searches. All identified randomised controlled trials were assessed using the Cochrane risk of bias assessment. Data were extracted using Cochrane data collection forms. Outcomes of interest underwent random-effects analysis using RevMan 5.3. The review protocol was registered with PROSPERO prior to commencement (CRD42019155733).

1 University Hospitals of Derby and Burton NHS Trust; University of Nottingham; Sandwell and West Birmingham Hospitals NHS Trust, UK
2 City Hospital, Birmingham, UK
3 University of Texas Health Science Center, San Antonio, Texas, USA
4 Life and Health Sciences, Aston University, Birmingham, UK
Address for correspondence: Dr Thomas SJ Crabtree
Department of Diabetes, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE
E-mail: t.crabtree@nhs.net
https://doi.org/10.15277/bjd.2020.247

THE BRITISH JOURNAL OF DIABETES
Results

Of 45 articles identified by initial searches, three randomised controlled trials were accepted for meta-analysis of the primary outcomes of HbA1c and FPG (Figure 1). Two further identified studies were not included in the meta-analysis due to their use of placebo subtracted values rather than mean and SD for the individual arms. These will be discussed in the narrative. Baseline characteristics, study size, dose of imeglin and follow-up of the five identified studies are shown in Table 1.

Primary outcomes

Baseline mean±SD values for HbA1c and FPG in the three included studies were 8.2±0.6% (66±7 mmol/mol) and 10.3±1.9 mmol/L, respectively. The meta-analyses of HbA1c and FPG data from the three included studies are shown in Figure 2, along with risk of bias assessment for these studies.12–14 The random-effects model determined that imeglin 1500 mg twice daily was associated with reductions of HbA1c of −0.63% (95% CI −0.84 to −0.42) (−6.6 mmol/mol, 95% CI −8.8 to −4.4) and reductions of FPG by −0.52 mmol/L (95% CI −0.80 to −0.24) compared with placebo.

Two studies not included in the meta-analysis showed significant placebo-subtracted decreases in HbA1c and FPG with imeglin.15 16 In a 24-week phase 2b monotherapy trial with 299 Japanese patients, imeglin (1500 mg twice daily) was associated with placebo-corrected reductions of HbA1c (by −1.0%) (−11 mmol/mol) and FPG (by −1.4 mmol/L). In the recent 24-week phase 3 monotherapy trial, placebo-corrected reductions in HbA1c and FPG amongst 213 participants were −0.87% (−9 mmol/mol) and −1.1 mmol/L, respectively, with imeglin (1000 mg twice daily). Each of these results was significant to p<0.001, but the confidence intervals or variances were not reported.

Secondary outcomes

Numerically fewer treatment-emergent adverse events were noted with imeglin compared with placebo in two of the three included studies,12,14 and a small increase (3.9%) was noted in the other study.13 None of these events was considered serious, and the most common side effects were gastrointestinal, affecting ≤6% of patients taking imeglin where reported.12,14 No adverse cardiovascular events were noted.

Hypoglycaemia (severity not defined) was noted on four occasions in one study during the run-in phase (ie, before commencing imeglin),14 but no hypoglycaemia events were identified with imeglin in this or any of the other studies. One study noted a ‘slight decrease’ in weight when participants received imeglin in combination with metformin compared with metformin alone.13 No other studies reported body weight outcome.

Discussion

The present meta-analysis confirms that the novel glucose-lowering agent imeglin consistently reduced HbA1c and FPG during randomised controlled trials in type 2 diabetes patients when used either as monotherapy or add-on to metformin or sitagliptin. Overall reductions of HbA1c (by 0.63%) and FPG (by 0.52 mmol/L) with the 1500 mg twice daily dose of imeglin are comparable with efficacy data reported for some other classes of glucose-lowering agents such as dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors.17

Adverse effects were mostly minor and related to the gastrointestinal tract, indicating that imeglin was generally well tolerated. Severe hypoglycaemia was not identified with imeglin, consistent with agents that exhibit similar glucose-lowering efficacy.17 However, evidence from larger studies will be required to confirm this. Further evidence of the effect of imeglin on body weight is also needed.
Table 1  Characteristics and main findings of randomised controlled studies identified from systematic searches assessing imeglimin versus placebo included in systematic review

| Study                  | Design                                      | Participants                                                                 | Arms                                                                 | Results                                                                 |
|------------------------|---------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|
| Pirags et al, 2012      | 8-week, multicentre, randomised, four-arm parallel group study. Patients on no other therapy | n=95  Mean age in imeglimin group 1500 mg BD group 60.0 years Mean BMI in imeglimin group 32.2 kg/m² All arms were broadly similar | Patients randomised to imeglimin 500 mg BD; imeglimin 1500 mg BD; metformin 850 mg BD or placebo | Imeglimin 1500 mg BD Changed HbA₁C −0.18% vs +0.31% in placebo Changed FPG −1.02 mmol/L vs +0.78 mmol/L in placebo Fewer adverse events with imeglimin vs placebo Adverse events mostly GI |
| Fouqueray et al, 2013   | 12-week, multicentre, randomised, double-blind, placebo controlled, parallel group study. Patients inadequately controlled on maximum dose of metformin | n=156  Age range 18-70 years BMI not reported | Patients randomised to combination therapy with metformin + imeglimin 1500 mg BD or placebo | Imeglimin 1500 mg BD Changed HbA₁C −0.65% vs −0.21% in placebo Changed FPG −0.91 mmol/L vs +0.36 mmol/L in placebo Numerical increase (3.9%) of patients with adverse events with imeglimin vs placebo *Slight decrease* in body weight observed |
| Fouqueray et al, 2014   | 12-week, multicentre, randomised, double-blind, placebo controlled, parallel group study. Patients inadequately controlled on sitagliptin alone. | n=170  Age range 18-75 years BMI 20-40 kg/m² | Patients randomised to combination therapy with sitagliptin + imeglimin 1500 mg BD or placebo | Imeglimin 1500 mg BD Changed HbA₁C −0.6% vs +0.12% in placebo Changed FPG −0.93 mmol/L vs +0.11 mmol/L in placebo Fewer adverse events with imeglimin vs placebo |
| Dubourg et al, 2017     | 24-week, multicentre, randomised, double-blind, placebo controlled trial. Japanese patients on no other therapy. | n=299  Mean age in imeglimin group 1500 mg BD group 57.6 years Mean BMI in imeglimin 1500 mg BD group 26.8 kg/m² All arms broadly similar | Patients were randomised to imeglimin 500 mg BD, imeglimin 1000 mg BD or placebo | Imeglimin 1500 mg BD Placebo corrected reduction in HbA₁C −1.0% Placebo corrected reduction in FPG −1.4 mmol |
| TIMES 1 trial           | Topline results as per Poxel Website         | n=213  Baseline characteristics not available | Patients were randomised to imeglimin 1000 mg BD or placebo | Imeglimin 1000 mg BD Placebo corrected reduction in HbA₁C −0.87% Placebo corrected reduction in FPG −1.1 mmol |

*Not included in meta-analysis due to variation in format of reported outcomes.

BD, twice daily; BMI, body mass index; FPG, fasting plasma glucose; GI, gastrointestinal.

Figure 2.  Forest plot of meta-analysis of imeglimin versus placebo for (a) HbA₁C (%) and (b) fasting plasma glucose (mmol/L) using a random-effect model. Risk of bias assessment is included

(a) Study or subgroup   | Imeglimin         | Placebo          | Std. Mean difference | Std. Mean difference |
|-----------------------|-------------------|------------------|----------------------|---------------------|
| Pirags et al, 2012    | -0.18 (0.9)       | 0.31 (0.88)      | 0.54 (−1.04, −0.04)  | 2012                |
| Fouqueray et al, 2013 | -0.65 (0.82)      | 0.21 (0.83)      | 0.53 (−0.87, −0.19)  | 2013                |
| Fouqueray et al, 2014 | -0.99 (0.99)      | 0.01 (0.83)      | 0.75 (−1.06, −0.43)  | 2014                |
| Total (95% CI)        | 180               | 190              | -0.63 (−0.84, −0.42) |                     |

Heterogeneity: T² = 0.00; Ch² = 0.98, df = 2 (p = 0.61); I² = 0%
Test for overall effect: z = 5.90 (p < 0.00001)

(b) Study or subgroup   | Imeglimin         | Placebo          | Std. Mean difference | Std. Mean difference |
|-----------------------|-------------------|------------------|----------------------|---------------------|
| Pirags et al, 2012    | -0.18 (0.9)       | 0.31 (0.88)      | 0.54 (−1.04, −0.04)  | 2012                |
| Fouqueray et al, 2013 | -0.65 (0.82)      | 0.21 (0.83)      | 0.53 (−0.87, −0.19)  | 2013                |
| Fouqueray et al, 2014 | -0.99 (0.99)      | 0.01 (0.83)      | 0.75 (−1.06, −0.43)  | 2014                |
| Total (95% CI)        | 180               | 190              | -0.63 (−0.84, −0.42) |                     |

Heterogeneity: T² = 0.00; Ch² = 0.98, df = 2 (p = 0.61); I² = 0%
Test for overall effect: z = 5.90 (p < 0.00001)

(1) SD absent therefore average variance of other studies used in lieu (this is likely an overestimate of variance given Figure 2 in original paper)
Key messages

- Imeglimin is a novel, first in-class, glucose-lowering agent for the management of type 2 diabetes
- Imeglimin acts via a mitochondrial mechanism to increase glucose uptake by skeletal muscle, decrease hepatic glucose output and increase glucose-dependent insulin secretion
- Initial clinical trials show that imeglimin reduces HbA1c and fasting plasma glucose in type 2 diabetes, and is generally well tolerated

The bias assessment noted insufficient information about the allocation process and incomplete data that precluded more extensive analyses. Other limitations concerned the modest numbers of patients, the duration of the trials (longest 24 weeks) and the need for studies that assess the effects of imeglimin in different groups of type 2 diabetes patients. These should consider different ethnicities and co-morbidities, different stages of disease progression and different combinations of agents, including measures of long-term efficacy and safety.

These initial trials indicate that imeglimin exerts a significant glucose-lowering effect as monotherapy or in combination with metformin or sitagliptin, achieving comparable efficacy with some other classes of glucose-lowering agents. Imeglimin was well tolerated and showed an acceptable safety profile in studies to date. Larger, longer and more detailed trials are awaited to expand present information.

Conflict of interest TC has nothing to disclose. RAD Advisory Board: AstraZeneca, Novo Nordisk, Janssen, Boehringer-Ingelheim, Intarcia, Poxel - Honorarium. Research Support: Boehringer-Ingelheim, AstraZeneca, Janssen, Merck – Research Grant – (Investigator). Speaker’s Bureau: Novo-Nordisk, AstraZeneca – Honorarium (Speaker). REJR: speaker fees, and/or consultancy fees and/or educational sponsorships from AstraZeneca, BioQuest, GI Dynamics, Janssen and Novo Nordisk. CB reports personal fees from Poxel, outside the submitted work.

Funding None.

References
1. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19
2. Vial G, Chauvin M-A, Bendridi N, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 2015;64:2254–64. https://doi.org/10.2337/db14-1220
3. Patti M-E, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010;31:364–95. https://doi.org/10.1210/er.2009-0027
4. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664–71. https://doi.org/10.1056/NEJMoa031314
5. Li J, Shirakawa, Y, Tagashi T, et al. Effects of imeglimin on insulin secretion, beta-cell proliferation, or apoptosis in mouse islets. J Diabetes Invest 2018;9:12. https://doi.org/10.1111/jdi.12937
6. Pacini G, Mari A, Fouqueray P, et al. Imeglimin increases glucose-dependent insulin secretion and improves beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2015;17:541–5. https://doi.org/10.1111/dom.12452
7. Hallakou-Bozec S, Kergoat M, Bolze S, Lebovitz HE. Imeglimin preserves beta cell function and mass in male zucker diabetic fatty rats. Endocr Prac 2017;23:1. https://europepmc.org.proxy.unsw.edu.au/article/med/9984501
8. Lablanche S, Tubbs E, Cottet-Rousselle C, et al. Imeglimin protects INS-1 cells and human islets against high glucose- and high fructose-induced cell death by inhibiting the mitochondrial FTO opening. Diabetes 2018;67(Suppl 1):B1–B1-OR. https://doi.org/10.2337/db18-81-OR
9. Detaille D, Vial G, Borelet A-L, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discovery 2016;2:15072. https://doi.org/10.1038/cddiscovery.2015.72
10. Lachaux M, Nicol L, Hamzaou M, et al. Imeglimin protects from diabetic cardiomyopathy in the obese zucker rat. Diabetes 2017;66(Suppl 1):2054-P
11. Lachaux M, Souille M, Remy-Jouet I, et al. Acute imeglimin treatment improves metabolic syndrome-related cardiac and coronary endothelial dysfunction in the zucker fafa rat. Eur Heart J 2018;39:484–5.
12. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glinin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 2012;14:852–8. https://doi.org/10.1111/j.1463-1326.2012.01611.x
13. Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2013;36:565–68. https://doi.org/10.2337/dc12-0453
14. Fouqueray P, Pirags V, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care 2014;37:1924–30. https://doi.org/10.2337/dc13-2349
15. Dubourg J, Ueki K, Watada H, et al. Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial. Diabetologia 2017;60(Suppl 1):E43.
16. Poxel Pharma. Poxel and Sumitomo Dainippon Pharma announce positive top-line results for imeglimin phase 3 trial (TIMES 1) in Japan for the treatment of type 2 diabetes. 9 April 2019. https://www.poxelpharma.com/en/news-media/press-releases/detail/117/poxel-and-sumitomo-dainippon-pharma-announce-positive (accessed 23 March 2020).
17. Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther 2015;98:170–84. https://doi.org/10.1002/cpt.144